Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Florence
Clinical trial register · Italy

Clinical Trials in Florence, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6778 matching records held by the registry are in this view. Synced 08 Oct 2026, 03:19 UTC
6778
Studies in scope
all four open statuses
4069
Recruiting now
open to new participants
1018
Lead sponsors
across recruiting studies
Top sites
Milan 51 Bologna 30 Roma 25 Florence 25 Naples 22
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca57 Meyer Children's Hospital IRCCS41 Merck Sharp & Dohme LLC25 Eli Lilly and Company25 Novartis Pharmaceuticals24 Clear sponsor filter
Site location
Milan51 Bologna30 Roma25 Florence25 Naples22
All 68 locations
Target enrolment
to

Trials with a site in Florence

25 of 6778 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Not yet open
Eli Lilly and Company
Phase 3
170
Ancona, Florence, Genova, Messina, Milan, Naples, Verona
2026-09
Not yet open
Eli Lilly and Company
Phase 3
150
Florence, Modena, Novara, Parma, Roma
2026-09
Recruiting
Eli Lilly and Company
Phase 2
60
Florence, Milan, Monza, Negrar, Roma, Rozzano
2026-05-04
Recruiting
Eli Lilly and Company
Phase 2
60
Florence, Milan, Monza, Negrar, Roma, Rozzano
2026-05-04
Recruiting
Eli Lilly and Company
Phase 4
150
Alessandria, Florence, Messina, Monza, Perugia, Rome, Terni
2026-03-09
Recruiting
Eli Lilly and Company
Phase 3
300
Ancona, Florence, Messina, Naples, Novara, Padova, Verona
2026-02-05
Recruiting
Eli Lilly and Company
Phase 3
150
Ancona, Bologna, Cagliari, Florence, Milan, Naples, Novara, Padova
2026-01-12
Recruiting
Eli Lilly and Company
Phase 3
800
Bergamo, Bologna, Florence, Genova, Meldola, Milan, Misterbianco, Monza
2025-12-22
Recruiting
Eli Lilly and Company
Phase 3
7,140
Bologna, Brescia, Ferrara, Florence, Genova, Milan, Monza, Palermo
2025-12-01
Recruiting
Eli Lilly and Company
Phase 3
4,500
Bergamo, Bologna, Florence, Milan, Naples, Padova, Palermo, Roma
2025-10-15
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Arzignano, Baggiovara, Bologna, Caserta, Ferrara, Ferrara (Cona), Florence, Genova
2025-09-02
Active, closed
Eli Lilly and Company
Phase 3
905
Bologna, Catanzaro, Florence, Milan, Naples, Padova, Roma, Torino
2025-04-25
Recruiting
Eli Lilly and Company
Phase 3
150
Florence, Novara, Verona
2024-11-18
Recruiting
Eli Lilly and Company
Phase 3
125
Florence, Modena, Novara, Parma, Roma, Verona
2024-11-18
Active, closed
Eli Lilly and Company
Phase 2
143
Bologna, Brescia, Fano, Florence, Gazzi - Messina, Milan, Modena, Monserrato
2024-10-10
Recruiting
Eli Lilly and Company
Phase 3
510
Florence, Milan, Naples, Padova, Pisa, Rome, Vimercate
2024-04-29
Recruiting
Eli Lilly and Company
Phase 3
90
Alessandria, Bergamo, Bologna, Florence, Milan, Roma
2024-03-13
Active, closed
Eli Lilly and Company
Phase 3
17,300
Arzignano, Baggiovara, Bologna, Cinisello Balsamo, Ferrara, Florence, Genova, Milan
2024-03-05
Active, closed
Eli Lilly and Company
Phase 3
15,374
Bari, Bologna, Como, Ferrara, Florence, Latina, Padova, Palermo
2022-10-11
Active, closed
Eli Lilly and Company
Phase 3
8,000
Ancona, Bergamo, Bologna, Brindisi, Candiolo, Florence, Genova, Milan
2022-10-04
Active, closed
Eli Lilly and Company
Phase 3
874
Naples, Aviano, Rome, Genoa, Florence, Padova
2021-10-04
Recruiting
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
150
Bergamo, Bologna, Florence, Milan, Roma, Rome
2021-05-26
Active, closed
Eli Lilly and Company
Phase 3
101
Naples, Genoa, Milan, Florence, Brescia
2021-04-13
Active, closed
Eli Lilly and Company
Phase 3
30
Milan, Florence
2019-10-16
Active, closed
Eli Lilly and Company
Phase 2
110
Bologna, Florence
2012-05-22
Rows per page Showing 1–25 of 25
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-italy/city/florence

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,778 studies in total at the last sync on 08 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 25 of those studies with a site in Florence that also match the filters currently applied.

How many clinical trials are recruiting in Florence?

14 of the 25 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:19 UTC sync. A further 2 have not yet opened recruitment, 9 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Florence), 25 studies
PhaseStudiesRecruitingShare
Phase 3201180%
Phase 24216%
Phase 4114%

Most active sponsors

Lead sponsors with the most studies (Florence)
Lead sponsorStudiesRecruiting
Eli Lilly and Company2514
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.